Edward Pershing - Sep 30, 2024 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
CEO, Director
Signature
/s/ Edward Pershing
Stock symbol
PVCT
Transactions as of
Sep 30, 2024
Transactions value $
$0
Form type
4
Date filed
9/30/2024, 06:56 PM
Previous filing
Sep 20, 2024
Next filing
Oct 17, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT Series D-1 Convertible Preferred Stock Award $0 +168K +11.67% $0.00 1.61M Sep 30, 2024 Common Stock 1.68M Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F2 The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.